A Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer - Full Text View - ClinicalTrials.gov

A Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer - Full Text View - ClinicalTrials.gov

A Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

This study is currently recruiting participants.

Verified March 2012 by University of Michigan Cancer Center

First Received on March 30, 2012.   Last Updated on April 16, 2012   History of Changes

Sponsor:	University of Michigan Cancer Center
Information provided by (Responsible Party):	Ronald Buckanovich, University of Michigan Cancer Center
ClinicalTrials.gov Identifier:	NCT01579812

  Purpose

The primary objective of this study is to determine if metformin administered as the time of traditional adjuvant chemotherapy to women with advanced ovarian, primary peritoneal or fallopian tube cancer will improve recurrence-free survival at 18 months compared to controls.

media: Cheap Diabetes Drug May Be Newest Weapon Against Cancer

Cheap Diabetes Drug May Be Newest Weapon Against Cancer

"Researchers warned there is still much work to be done before they can definitively say whether metformin can be used as a cancer drug."

Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and Chemosensitivity

Use of metformin and the risk of ovarian cancer: A case-control analysis

OBJECTIVE:

To explore the association between use of metformin or other antidiabetic drugs and the risk of ovarian cancer.

CONCLUSION:

In this large epidemiological study long-term use of metformin, but not of sulfonylureas, was associated with a tendency towards a decreased risk of ovarian cancer. Long-term use of insulin was associated with an increased risk of ovarian cancer.